News & Media
US Food and Drug Administration (FDA) approved the use of Teplizumab under the brand name Tzield, an immunotherapy drug, which has been shown to significantly delay the onset of type 1 diabetes. This...
Thursday November 3, 2022 9:00a-5:00p Join us to celebrate the 20th anniversary of the UCSF Diabetes Center. Hear from our distinguished researchers who will share updates on their groundbreaking...
Last year the World Health Organization (WHO) launched the NCD LAB, an initiative leveraging community-driven grassroots innovations with the potential to be game changers in beating non-communicable...
A personal investigation into the lifelong implications of his type 1 diabetes culminated in a $7 million gift from Mike Gordon, co-founder of Meritech Capital Partners, and his wife, Loren, to help...
When mice with atopic dermatitis—a common type of allergic skin inflammation—are treated with drugs that target the immune system, their thickened, itchy skin generally heals quickly. Sagar Bapat, MD...
Stephen Gitelman MD, moderates panel discussion with Sarah Kim MD, Audrey Parent PhD, and Shylaja Srinivasan MD
From UCSF School of Medicine Bridges curriculum, pioneering a new approach to medical education to prepare physicians for practice in the 21st century, Allison Xu discusses the biology behind obesity.
Premature senescent beta cells during the development of Type 1 diabetes
For over a half century, UCSF researchers and clinicians have been making breakthrough discoveries that have improved diabetes treatment and care for individuals with diabetes and their families. Ten...